

Rifapentine, Terbinafine Hcl, Imiquimod, Butenafine HCL passed GMP inspection

In June and September of 2017, 4 API products of Chongqing Huapont Pharma transferred from Sichuan Medshing Pharmaceutical have passed the current inspection of CFDA, which include: **Rifapentine, Terbinafine Hcl, Imiquimod, Butenafine HCL**. GMP of the 4 products will be receive in early 2018.

Since 2017, 8 API products of Sichuan Medshine: **Rifapentine, Rifabutine, Terbinafine Hcl, Imiquimod, Butenafine HCL, Benzoyl peroxide, Valaciclovir, Adapalene** are gradually transferred to Chongqing Huapont Huapont Shengchem. GMP of the 8 API products will be received in the first half year of 2018.

Please do not hesitate to contact us:

Email: mike.wang@huapont.cn

Tel: 0086-23-67886928 | Fax: 0086-23-67886927

www.huapont.cn

About Sichuan Medshine

Sichuan Medshing is a Pharmaceutical company located in Wenjiang, Sichuan province which is strong in the area of dermatology and anti-TB. Chongqing Huapont merged Sichuan Medshing Pharmaceutical in June of 2013 with ¥100.5 million which greatly enriched their production line.

